ADC Therapeutics SA (ADCT)
1.29
-0.01
(-0.77%)
USD |
NYSE |
Sep 09, 13:52
ADC Therapeutics Debt to Equity Ratio : -0.5152 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.5152 |
| March 31, 2026 | -0.5392 |
| December 31, 2025 | -2.365 |
| September 30, 2025 | -1.920 |
| June 30, 2025 | -2.263 |
| March 31, 2025 | -1.918 |
| December 31, 2024 | -0.607 |
| September 30, 2024 | -0.7244 |
| June 30, 2024 | -0.9448 |
| March 31, 2024 | -0.6394 |
| December 31, 2023 | -0.839 |
| September 30, 2023 | -2.280 |
| June 30, 2023 | -14.39 |
| Date | Value |
|---|---|
| March 31, 2023 | 3.262 |
| December 31, 2022 | 1.477 |
| September 30, 2022 | 1.113 |
| June 30, 2022 | 0.9619 |
| March 31, 2022 | 0.7663 |
| December 31, 2021 | 0.8411 |
| September 30, 2021 | 0.8393 |
| June 30, 2021 | 0.6111 |
| March 31, 2021 | 0.3351 |
| December 31, 2020 | 0.343 |
| September 30, 2020 | 0.3012 |
| June 30, 2020 | 0.7512 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 0.3961 |
| AC Immune SA | 0.1166 |
| CRISPR Therapeutics AG | 0.4487 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 279.38M |
| Total Liabilities (Quarterly) | 507.58M |
| Shareholders Equity (Quarterly) | -228.20M |
| Current Ratio | 3.031 |
| Net Debt Paydown Yield | 49.76% |